Gilteritinib
Generic name: Gilteritinib
Brand names: Xospata
Dosage form: oral tablet (40 mg)
Drug class:
Multikinase inhibitors
Usage of Gilteritinib
Gilteritinib is used to treat acute myeloid leukemia (AML) in adults with an abnormal FLT3 gene. Your doctor will test you for this gene.
Gilteritinib is given after other cancer treatments did not work or have stopped working.
Gilteritinib may also be used for purposes not listed in this medication guide.
Gilteritinib side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Gilteritinib can cause a condition called differentiation syndrome, which affects blood cells and can be fatal if not treated. This condition may occur within 2 days to 3 months after you start taking gilteritinib.
Seek medical help right away if you have symptoms of differentiation syndrome:
Gilteritinib may cause serious side effects. Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects of gilteritinib may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Gilteritinib
You should not use gilteritinib if you are allergic to it.
Tell your doctor if you have ever had:
Before you take gilteritinib, your heart function may need to be checked using an electrocardiograph or ECG (sometimes called an EKG).
Gilteritinib can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.
Do not breastfeed while using this medicine, and for at least 2 months after your last dose.
Relate drugs
- Afatinib
- Alecensa
- Alectinib
- Alunbrig
- Avapritinib
- Ayvakit
- Cobimetinib
- Cotellic
- Crizotinib
- Balversa
- Binimetinib
- Braftovi
- Brigatinib
- Capmatinib
- Ceritinib
- Dabrafenib
- Deucravacitinib
- Encorafenib
- Entrectinib
- Erdafitinib
- Fedratinib
- Futibatinib
- Gavreto
- Gilotrif
- Gilteritinib
- Infigratinib
- Inrebic
- Jakafi
- Koselugo
- Larotrectinib
- Litfulo
- Lorbrena
- Lorlatinib
- Lytgobi
- Mekinist
- Mektovi
- Midostaurin
- Momelotinib
- Nintedanib
- Ofev
- Ojjaara
- Pacritinib
- Pemazyre
- Pemigatinib
- Pexidartinib
- Pralsetinib
- Qinlock
- Retevmo
- Ripretinib
- Ritlecitinib
- Rozlytrek
- Ruxolitinib
- Ruxolitinib (Oral)
- Rydapt
- Selpercatinib
- Selumetinib
- Sotyktu
- Tabrecta
- Tafinlar
- Tepmetko
- Tepotinib
- Trametinib
- Truseltiq
- Turalio
- Ukoniq
- Umbralisib
- Vemurafenib
- Vitrakvi
- Vonjo
- Xalkori
- Xospata
- Zelboraf
- Zykadia
How to use Gilteritinib
Usual Adult Dose for Acute Myeloid Leukemia:
120 mg orally once a day until disease progression or unacceptable toxicityComments:-Response may be delayed. In the absence of disease progression or unacceptable toxicity, patients should be treated for a minimum of 6 months to allow time for a clinical response.-Select patients for the treatment of AML with this drug based on the presence of FLT3 mutations in the blood or bone marrow.Use: For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation.
Warnings
Gilteritinib can cause a condition called differentiation syndrome, which affects blood cells and can be fatal if not treated. This condition may occur within 2 days to 3 months after you start taking gilteritinib.
Seek medical help right away if you have symptoms of differentiation syndrome: fever, cough, trouble breathing, bone pain, rapid weight gain, or swelling in your arms, legs, underarms, groin, or neck.
What other drugs will affect Gilteritinib
Other drugs may affect gilteritinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions